Did you miss "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.
In an "Executive Decision" segment, Cramer sat down with Juan Ramon Alaix, CEO of Zoetis (ZTS) , the animal health-care provider that just posted a five-cents-a-share earnings beat on a 6% rise in revenues. Shares of Zoetis are up 13% over just the past month.
Alaix said that Zoetis continues to invest in China, a market that is expanding for both companion animal and livestock vaccines. He said his company also continue to innovate and now has over 300 product lines to treat eight different species.
Zoetis also has an exciting product pipeline with new pain management treatments for both dogs and cats.
When asked what a lower tax rate would mean for Zoetis, Alaix explained that their capital allocation plans always include investing in their business, additional mergers and acquisitions, and also returning capital to shareholders via dividends and share buyback programs.
With a solid long-term trend behind them, Cramer said that Zoetis continues to be a fabulous story.
Cramer and the AAP team want to use the pullback from Nucor's (NUE) highs as a chance to continue to build their position. Find out what they're telling their investment club members; get a free trial subscription to Action Alerts PLUS.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To read a full recap of this episode of "Mad Money," click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.